TLPH
$0.84
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which ...
Recent News
This Talphera Insider Increased Their Holding By 138% Last Year
Looking at Talphera, Inc.'s ( NASDAQ:TLPH ) insider transactions over the last year, we can see that insiders were net...
Talphera (TLPH) Q3 2025 Earnings Call Transcript
Beyond the NIAID opportunity, the recent investments were catalyzed by our efforts at the end of last year to restructure the nephro clinical study, which included changing the target profile for clinical sites and investigators and approaching the FDA with various study protocol changes, including the reduction of the study size from 166 to 70 patients with a goal of accelerating the completion of the study. The results of this restructuring were evident last quarter with the acceleration in the enrollment rate from our existing sites, which continued into the third quarter.
Talphera Inc (TLPH) Q3 2025 Earnings Call Highlights: Strategic Investments and Regulatory ...
Talphera Inc (TLPH) secures crucial financing and navigates regulatory pathways while facing delays in clinical study site activations.
Talphera: Q3 Earnings Snapshot
SAN MATEO, Calif. AP) — Talphera, Inc. TLPH) on Wednesday reported a loss of $4.4 million in its third quarter.
BC-Most Active Stocks
td class="col-issue">Next Technology Holding Inc.